Drugs.com - Clinical Trials

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial of Efruxifermin in the New England Journal of Medicine

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need...

May 12, 2025 - 23:59
 0
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial of Efruxifermin in the New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need...
Read More

Tags:

Previous Article

Farmers Sued Over Deleted Climate Data. So the Government Will Put It Back.

Next Article

US-China tariffs pause ‘positive’ but uncertainty remains – analyst

Related Posts

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

May 12, 2025  0

Theravance Biopharma Presents Two New Ampreloxetine Analyses

Theravance Biopharma Presents Two New Ampreloxetine Ana...

May 12, 2025  0

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

May 12, 2025  0